Overproduction of urokinase-type plasminogen activator (uPA) and metalloproteases (MMPs) is strongly correlated with tumorigenicity and with invasive and metastatic phenotypes of human and experimental tumors. We demonstrated previously that overproduction of uPA in tumor cells is mediated by a phospholipase D (PLD)-and protein kinase C-dependent mechanism. The oncogenic stimulus of v-Src and v-Ras results in the activation of PLD, which is dependent upon the monomeric GTPase RalA. We have therefore investigated whether RalA plays a role in uPA and MMP overproduction that is observed in response to oncogenic signals. We report here that NIH3T3 cells transformed by both v-Src and v-Ras, constitutively overproduce uPA and that expression of a dominant negative RalA mutant (S28N) blocks overproduction of uPA in both the v-Srcand v-Ras-transformed cells. v-Src and v-Ras also induced an upregulation of the activity of MMP-2 and MMP-9 as detected by zymograms, however only the vSrc induction correlated with MMP protein levels detected by Western blot analysis. The dominant negative RalA mutant blocked increased MMP-2 and 9 overproduction induced by v-Src, but not the increased activity of MMP-2 and 9 induced by v-Ras. And, consistent with a role for the RalA/PLD pathway in mitogenesis and tumor development, the dominant negative RalA mutant completely blocked tumor formation by v-Src-and v-Ras-transformed NIH3T3 cells injected subcutaneously in syngeneic mice. The data presented here implicate RalA and PLD as signaling mediators for tumor formation and protease production by transformed cells.
Introduction
Metastasis is the last and most lethal stage of tumor progression. This process follows several steps including the exit of tumor cells from the primary tumor, intravasation after degradation of the interstitial and the blood vessels extracellular matrix, dissemination through the lymphatic or arterial system, and ®nally extravasation, settlement, and growth in a distant organ (Hart et al., 1989) . In several of these steps, as well as during primary tumor organization, proteases like urokinase-type plasminogen activator (uPA) and metalloproteases (MMPs) are highly involved Ossowski, 1992) . Tumorigenicity has been described as being dependent on the expression of tumor-or host-derived proteases, since they enable the remodeling of the local tissue and angiogenesis, two critical steps for the successful development of a primary tumor Werb et al., 1996) . Strong correlations between uPA and/or MMP production and the invasive and metastatic ability of tumor cells have been described (Ossowski 1992; Moller 1993; Boyd 1996) . uPA is a serine-protease that converts plasminogen to active plasmin (Moller 1993; Yu and Schultz, 1990) . Enhanced pericellular proteolysis, primary tumor organization, and invasiveness are mediated via the uPA/ uPA receptor/plasmin system. Upregulation of uPA and the uPA receptor enables tumor cells to keep their surface completely saturated with these enzymes (Ossowski and Reich 1983; Yu et al., 1997) . MMPs are a group of matrix proteases, such as the type IV collagenases (MMP-2/gelatinase B, MMP-9/gelatinase A), which are implicated in tissue remodeling, angiogenesis, in¯ammation, invasion and metastasis (Matrisian, 1992) .
Tumor proteases like uPA and MMPs have been reported to be upregulated upon transformation by vSrc and v-Ras (Sato et al., 1993; Bell et al., 1993; Silberman et al., 1997; . Signaling pathways activated by v-Src and v-Ras (Burgering and Bos, 1995) include those involving phosphatidylinositol-3-kinase (Carpenter and Cantley, 1996) , protein kinase C (Song et al., 1991) , Raf-1 (Blobe et al., 1994 ) the extracellular regulated kinases (ERK-1 and 2) (Burgering and Bos, 1995) and phospholipase D (PLD) (Song et al., 1991) . It has been reported that Raf-1, MEK-1 and ERK1 mediate the signal leading to uPA, uPA receptor, and MMP-9 upregulation Gum et al., 1997) . We recently reported that overexpression of uPA in murine mammary adenocarcinoma cells is controlled by a PLD and protein kinase C-dependent pathway (Aguirre Ghiso et al., 1997) . Additionally, MMP-2 expression induced by laminin has been reported to be coupled to PLD activation (Reich et al., 1995) . PLD converts phosphatidylcholine to phosphatidic acid, which has been implicated in vesicle budding and transport, as well as the transduction of intracellular signals (Bi et al., 1997; Exton, 1998; Roth and Sternweis, 1997) . Phosphatidic acid may also be metabolized further to the biologically active diacylglycerol or lysophosphatidic acid (Foster, 1993; Exton, 1994) . PLD activity is increased in response to most, if not all, mitogenic signals (Foster, 1993; Exton, 1998) . A PLD activity was found to be associated with the Ras-family GTPase RalA, which is required for the activation of PLD by both v-Src and vRas (Jiang et al., 1995b) and the active complex includes PLD1, RalA and Arf (Luo et al., 1997 (Luo et al., , 1998 . In the present work, we have investigated the involvement of the RalA pathway in protease production and tumor formation induced by v-Src and v-Ras.
Results
uPA production is upregulated in v-Src-and v-Ras-transformed NIH3T3 cells Several reports have described increases in uPA production in response to transformation by v-Src and v-Ras (Bell et al., 1993; Silberman et al., 1997) . To establish whether uPA production is elevated in NIH3T3 cells in response to v-Src and v-Ras, we examined uPA expression levels in parental, and in vSrc-, and v-Ras-transformed NIH3T3 cells. As shown in Figure 1a , NIH3T3 cells secreted a 48 kDa plasminogen activator activity. This activity was completely blocked by 1 mM amiloride or an anticatalytic anti-uPA antibody, con®rming the identity of uPA. We then compared the uPA activity in conditioned medium (CM) from v-Src-and v-Rastransformed cells relative to that in the parental NIH3T3 cells. As shown in Figure 1b , both v-Src and v-Ras-transformed cells displayed increased levels of uPA activity relative to the parental NIH3T3 cells (Figure 1b) . Consistent with the increased uPA activity in v-Src and v-Ras-transformed cells, we also detected increased levels of uPA protein in these cells relative to the NIH3T3 cells (Figure 1c ).
Overproduction of uPA in v-Src-and v-Ras-transformed cells is mediated by RalA
We demonstrated previously that uPA production is dependent on PLD (Aguirre Ghiso et al., 1997) , and that the activation of PLD by v-Src and v-Ras is dependent upon RalA (Jiang et al., 1995b) . We therefore wished to determine whether the elevated uPA levels observed in v-Src and v-Ras cells were dependent on RalA. To investigate the role of RalA on uPA overproduction induced by v-Src and v-Ras, we examined uPA activity in v-Src and v-Ras transformed cells stably expressing a mutant RalA protein (S28N), that functions as a dominant negative mutant for RalA (Jiang et al., 1995b; Urano et al., 1996) . This mutant blocked the increased PLD activity observed in response to both v-Src and v-Ras (Jiang et al., 1995b) . NIH3T3 cells transformed by either v-Src (Figure 2a and 2c) or v-Ras (Figure 2b and c) that expressed the dominant negative S28N-RalA ( Figure  2c ) showed signi®cant (P50.01) reductions in secreted uPA activity relative to the v-Src-and v-Rastransformed cells. Zymographic analysis showed that the uPA activity reduced by the dominant negative mutant of RalA corresponded to a reduction of a 48 kDa band (Figure 2d ). uPA protein levels as determined by Western blot analysis were also reduced in cells expressing the dominant negative RalA mutant ( Figure 2e ). As reported previously (Jiang et al., (Figure 2c and data not shown). Thus the reduced uPA levels in cells expressing the dominant negative RalA observed in Figure 2 are not due to reduced levels of the transforming oncoprotein in response to the RalA mutant.
Increased MMP-2 and MMP-9 production by v-Src, but not v-Ras is dependent on RalA It has been suggested that MMPs play a role in tumorigenesis and metastasis formation Werb et al., 1996) . Consistent with this hypothesis, increased MMP production has been reported in response to transformation by v-Src and v-Ras (Sato et al., 1993; . MMP production in tumor cells has been reported to be regulated by Ras (Sato et al., 1993) and dependent on PLD (Reich et al., 1995) . We therefore examined the role of RalA in the v-Src and v-Ras induction of MMPs. Zymograms of the CM from v-Src-and v-Rastransformed NIH3T3 cells showed an enhancement of proenzyme forms of a 72 kDa (Gelatinase B/MMP-2) and a 105 kDa (Gelatinase A/MMP-9) production compared to the control parental NIH3T3 cells (Figure 3a and b). MMP-2 and MMP-9 activity was also elevated in cell lysates from v-Src-and v-Rastransformed NIH3T3 cells (data not shown). v-Srctransformed cells expressing the dominant negative S28N RalA had substantially reduced levels of both (Figure 3c ). In contrast, the increased MMP-2 and MMP-9 activity induced by v-Ras was largely unaected by the S28N RalA mutant (Figure 3b) . Surprisingly, MMP-2 protein levels were not elevated in the v-Ras and v-Ras-S28N-Ral cells relative to the parental NIH3T3 cells ( Figure  3c ). This may explain why the dominant negative RalA prevents v-Src-induced increases MMP2, but not vRas-induced increases in MMP2. These data suggest two distinct mechanisms for elevating MMP-2 activity, one involving increased expression that is dependent upon RalA and one that involves a change in speci®c activity that is independent of RalA. Also of interest here were the additional low molecular weight bands observed for MMP-2 in both v-Ras-and v-Srctransformed cells (Figure 3a and b) . These low molecular weight species may represent the active forms of MMP-2. Interestingly, this form of MMP-2 was reduced in the v-Ras-transformed cells expressing the dominant negative RalA.
The dominant negative S28N RalA mutant prevents vSrc and v-Ras induced tumorigenicity
It was reported previously that the dominant negative S28N RalA inhibited v-Ras-and v-Raf-induced focus formation in cultured cells (Urano et al., 1996) . However, the inhibitory eect of the dominant negative RalA on focus formation was not as strong as that observed for dominant negative mutants of Ras and Raf on v-Src-induced transformation where colony formation in soft agar was inhibited almost completely (Qureshi et al., 1993; Jiang et al., 1995a,b) . We therefore investigated the eect of the dominant negative RalA on the ability of the v-Srcand v-Ras-transformed cells to form colonies in soft agar. As shown in Figure 4 , the dominant negative RalA mutant reduced the colony forming eciency of the v-Src-and v-Ras-transformed cells; however, as reported previously for the focus assay (Urano et al., 1996) , the dominant negative RalA only partially inhibited the colony formation. The S28N mutant reduced colony formation to about 75% that seen in the Ras-transformed cells and 54% of that seen in the Src-transformed cells. Another RalA mutant, D49N, which was slightly more eective at inhibiting colony formation where the eciency was reduced to 44 and 51% for the Ras and Src transformed cells respectively.
We next examined the eect of the dominant negative RalA on the ability to form tumors in syngeneic mice. Cell suspensions from v-Src-and vRas-transformed NIH3T3 cells and these cells expressing the S28N dominant negative RalA mutant were injected subcutaneously and tumor formation was monitored. As shown in Figure 5 , both v-Src and vRas cells developed subcutaneous tumors that could be detected after a 5 ± 7 day latency period, with an incidence of 50 and 55% respectively. In contrast, vSrc-and v-Ras-transformed cells expressing the dominant negative S28N RalA mutant did not develop subcutaneous tumors after injection when followed for 13 weeks. Tumor growth was evaluated up to 28 days when mice were sacri®ced and tumors removed. The histopathology revealed sarcoma-like tumors for both v-Src and v-Ras cell lines (data not shown). We also investigated whether the S28N RalA mutant interfered with the ability of v-Src-and v-Rastransformed cells injected into the tail vein to colonize in the lung. Upon injection of either v-Src-or v-Rastransformed cells into the tails of syngeneic mice, large colonies were detected in the lungs with high incidence (Table 1, Figure 6 ). The histopathological analysis showed the presence of not only subpleural but also parechymal nodules consisting of sarcomatoid cells and almost devoid of extracellular matrix (data not shown). The ability of v-Ras and v-Src cells to colonize the lung and form nodules was dramatically impaired in cells overexpressing the S28N-RalA mutant. As shown in Table 1 , both the incidence and number of lung colonies was signi®cantly reduced in mice inoculated with either v-Ras-or v-Src-transformed cells expressing the S28N RalA mutant. These data in Figures 4 ± 6 indicate that, while colony formation in soft agar is only partially dependent upon RalA, tumor formation is completely dependent upon RalA. Quanti®cation of the data is presented in Table 1 Discussion
In this report, we have investigated whether RalA plays a role in: (i) the upregulation of proteases; and (ii) tumor formation induced by the oncogenic v-Src and v-Ras. We ®rst observed that uPA expression levels were elevated in the CM from NIH3T3 cells transformed by v-Src and v-Ras. The upregulation of uPA could be reversed almost to the control levels by the expression of a dominant negative RalA mutant. We previously demonstrated that upregulation of uPA production is dependent upon PLD activity (Aguirre Ghiso et al., 1997), and since PLD1 activation by v-Src and v-Ras is dependent upon RalA (Jiang et al., 1995b; Luo et al., 1997) , the data presented here suggest that constitutive uPA overproduction in v-Src and v-Ras transformed cells is dependent upon a RalA-PLD1 signaling pathway. MMP activity was elevated in v-Src-transformed cells as detected by zymography and MMP protein was elevated as determined by Western blot analysis of cell lysates. The increased MMP production induced by vSrc, like increased uPA production, was reduced in the cells expressing the dominant negative RalA. However, the increased MMP activity observed in v-Rastransformed cells was insensitive to the dominant negative RalA. Interestingly, the increased MMP activity seen in zymograms was not observed at the MMP protein level in the v-Ras-transformed cells. This suggested that MMP activity may be regulated dierently in the v-Src and v-Ras-transformed cells and may explain why the dominant negative RalA prevents v-Src-induced increases in MMP2, but not vRas-induced increases in MMP2. These data suggest that the increased expression of MMP in the v-Srctransformed cells is dependent upon RalA and the elevated speci®c activity observed in the v-Rastransformed cells is independent of RalA. Exton and co-workers recently reported that MMP-9 secretion induced by phorbol esters was dependent on PLD and phosphatidic acid production (Williger et al., 1999) . It is unlikely that the mechanism was the same as that reported here since phorbol esters activate PLD by activating protein kinase C, which can activate PLD directly (Exton, 1998) . Thus, RalA is not likely to be involved in this case, however these data suggest the possibility that both RalA-dependent and independent mechanisms for MMP production exist.
More importantly, the studies presented here clearly indicate a role for RalA in v-Ras and v-Src induced tumorigenicity. Previous studies using cells in culture have suggested a role for RalA in mitogenic signaling and transformation (Urano et al., 1996) . However, dominant negative RalA mutants were less ecient in blocking the transformed phenotype than dominant negative mutants of Ras and Raf (Qureshi et al., 1993; Jiang et al., 1995a,b; Urano et al., 1996) . The studies provided here demonstrate conclusively that RalA inhibits completely the ability to form tumors.
Extracellular matrix remodeling by tumor cells has been proposed to be a necessary process for invasion and metastases establishment Werb et al., 1996) . The inhibitory eect of the dominant negative RalA on the upregulation of uPA expression in v-Src and v-Ras-transformed cells may be one of the mechanisms by which RalA-dominant negative mutant modulates tumorigenicity. This result does not directly correlate the eect of S28N RalA on MMP expression in v-Ras-S28N-RalA cells with the tumorigenicity data. An explanation for this result may derive from recent data showing that MMPs produced in cell culture or in vivo are non-functional in the absence of the uPA/ plasmin system (Mazzieri et al. 1997; Carmeliet et al., 1997) . Additional low MW bands that may represent the active form of MMPs were observed for MMP-2 in v-Ras cells, but were absent in v-Ras-S28N-Ral cells. These data suggest that uPA downregulation in v-Ras-S28N-RalA cells may account for the lack of the MMP-2 low MW bands (active form) since the active form is generated in response to uPA.
Reduced protease production and/or activity in cells expressing the dominant negative RalA may contribute to the more stringent eect of the dominant negative RalA mutant on tumor formation relative to colony formation in soft agar and focus formation. We have recently found that ®bronectin downregulation in NIH3T3 cells by v-Ras or v-Src is completely restored in v-Src or v-Ras cells expressing the S28N-RalA mutant (our unpublished data). This result suggests that reducing RalA signaling in v-Ras or v-Src transformed cells may restore the proper expression of not only uPA and MMPs in the case of v-Src, but of several other genes that in¯uence the tumorigenic and metastatic phenotype explaining the dramatic eects observed on tumorigenicity.
This report provides: (i) new insight on the role of RalA in the signals controlling protease expression; and (ii) demonstrates a role for RalA in tumor formation in the NIH3T3 model. In addition, our data are consistent with mounting information (Silberman et al., 1997; Gum et al., , 1997 Lengyel et al., 1996 Lengyel et al., , 1997 indicating that mitogenic signaling pathways stimulate the upregulation of uPA and MMPs. In this regard, an understanding of the mechanism(s) that tumor cells use to become tumorigenic and govern the production of proteases, which apparently includes the RalA-PLD1 pathway, may prove to be an important target for therapeutic intervention in tumor progression.
Materials and methods

Materials
G418 and Dulbecco's modi®ed Eagle medium (DMEM) were obtained from GIBCO/BRL Laboratories. Trypsin and amiloride were purchased from Sigma. Anti-murine uPA antibody was kindly provided by Dr G Hoyer-Hansen (Copenhagen, Denmark). Anti MMP-2 antibody was from Neomarkers (Union City, CA, USA). Anti-RalA antibody was from Trandsuction laboratories (Lexington, KY, USA). Biotinylated anti-rabbit IgG polyclonal antibody and streptavidin-alkaline-phosphatase were purchased from GIB-CO ± BRL. Puri®ed human urokinase was provided by Serono Laboratories (Buenos Aires). Plasminogen was purchased from Chromogenics (Sweden). Nitrocellulose membranes were purchased from BioRad (USA).
Cells and cell culture conditions
Cells were routinely maintained in DMEM supplemented with 10% fetal calf serum (GEN, Buenos Aires). The v-Src and v-Ras-transformed NIH3T3 cells and the v-Src-and vRas-transformed cells overexpressing the S28N RalA mutant were pooled clones generated as described previously (Jiang et al., 1995b) . Construction of the S28N RalA mutant was described previously (Urano et al., 1996) . Increased expression of the RalA (S28N) protein levels was veri®ed by Western blot analysis (data not shown). For growth of cells in soft agar, 1610 3 cells were suspended in top agar (DMEM, 20% calf serum, 0.38% agar) and overlaid onto hardened bottom agar (DMEM, 20% calf serum, 0.7% agar) as described previously (Qureshi et al., 1993) . In all experiments as a control NIH3T3 cells were vector (pZipneo)-transfected as described previously (Jiang et al., 1995a,b) .
Preparation of conditioned media (CM) and cell lysates uPA activity was investigated in CM and cell lysates. Brie¯y, semicon¯uent cell monolayers were washed in phosphate buer saline to eliminate serum. Serum-free DMEM/0.5% bovine serum albumin/25 mM HEPES was added and incubation was continued for 24 h. CM was harvested, centrifuged (600 g), concentrated with a Centricon ®lter (MW cut o 30 000), aliquoted, stored at 7408C, and used only once after thawing. The remaining monolayers were washed, scrapped and sonicated at 48C; protein content determinations were performed and the cell lysate samples were then stored at 7408C and used only once after thawing.
Zymography and radial caseinolysis for detection of uPA activity SDS-polyacrylamide gel electrophoresis was performed as described previously (Aguirre-Ghiso et al., 1997), using 9% separating and 4% stacking gels. Gels were washed with 2.5% Triton X-100, and incubated on the surface of a plasminogen-rich casein-agarose underlay, as described previously (Aguirre Ghiso et al., 1997 , Saksela, 1981 . To con®rm uPA activity in the zymograms, plasminogen-caseinagarose underlays were prepared with an anticatalytic uPA antibody, amiloride (1 mM) with or without plasminogen. uPA activity was quanti®ed by a radial caseinolysis assay (Saksela, 1981) , using plasminogen-rich (2 mg/ml) caseinagarose plates. uPA activity was referenced to a standard urokinase curve (0.1 ± 100 IU/ml) and normalized to total cell protein.
Western blot and densitometry CM was collected as described above, electrophoresed and then transferred to nitrocellulose. The ®lter was probed with or without rabbit IgG anti-murine uPA antibody and revealed with a biotinylated-IgG anti-rabbit antibody. The streptavidin-alkaline-phosphatase system was used to develop the signal (Alonso et al., 1993) . Protein bands were quantitated with a Molecular Analyst TM/PC Densitometer Model GS-700 (Bio-Rad USA) and analysed with the Image Analysis Software for Model GS-700 (Bio-Rad USA) (Aguirre-Ghiso et al., 1997).
Detection of MMP production
Collagenolytic activity present in CM or cell lysates was determined by electrophoresis in SDS-polyacrylamide gels copolymerized with 0.1% gelatin as described previously (Pittman, 1985) . After electrophoresis, gels were washed in 2% Triton X-100, washed with distilled water and incubated for 48 ± 72 h in 0.25 M Tris-HCl: 1 M NaCl: 25 mM CaCl 2 (pH 7.4) for speci®c activity detection, or in the same solution containing 40 mM EDTA to detect non-speci®c activity. Gels were ®xed and stained with Coomassie Blue. Activity bands were visualized by negative staining. The activity bands for MMP or uPA activity were quantitated with a densitometer as described above.
Mice
Inbred BALB/c mice 2 ± 4 months old, were obtained from the Animal Production Division of the Research Area of the Institute of Oncology`Angel H/Roo'. Mice were bred with a 12 h light-12 h darkness cycle and a constant temperature of 208C. Water and food were administered ad libitum.
Tumorigenicity assays
To evaluate local tumor growth, NIH3T3 cells, v-Src-and vRas-transformed cells, and v-Src-and v-Ras-transformed cells expressing the S28N dominant negative RaIA mutant were trypsinized, washed three times with DMEM, and allowed to recover for 1 h. Cells were assayed for viability with the Trypan Blue exclusion test prior to injection. Tumorigenicity was then examined in two ways. Method 1: Cells were injected in the subcutaneous¯ank of syngeneic BALB/c mice (4610 5 cells in 0.2 ml of DMEM). Growth kinetics of tumors were established by measuring the average tumor diameter with a caliper three times per week. Method 2: cells prepared as above were injected into the lateral tail vein of normal mice (3610 5 cells in 0.3 ml of DMEM). Growth of these cells was then investigated by histopathological analysis of the lungs and other organs 21 days after injection. Lung subpleural tumor nodules were counted under a stereoscopic magni®er after ®xation for 5 h with Bouin's solution.
